Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Change in Account Payables: 2012-2025

Historic Change in Account Payables for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to -$723,000.

  • Enanta Pharmaceuticals' Change in Account Payables rose 52.99% to -$723,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 million, marking a year-over-year decrease of 216.67%. This contributed to the annual value of -$1.3 million for FY2025, which is 216.67% down from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Change in Account Payables stood at -$723,000 for Q3 2025, which was up 44.08% from -$1.3 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' 5-year Change in Account Payables high stood at $6.6 million for Q1 2023, and its period low was -$5.1 million during Q2 2022.
  • For the 3-year period, Enanta Pharmaceuticals' Change in Account Payables averaged around -$199,091, with its median value being -$723,000 (2025).
  • In the last 5 years, Enanta Pharmaceuticals' Change in Account Payables soared by 1,796.21% in 2021 and then plummeted by 2,923.33% in 2022.
  • Enanta Pharmaceuticals' Change in Account Payables (Quarterly) stood at -$1.7 million in 2021, then spiked by 58.75% to -$686,000 in 2022, then soared by 854.23% to $5.2 million in 2023, then tumbled by 103.25% to -$168,000 in 2024, then soared by 52.99% to -$723,000 in 2025.
  • Its Change in Account Payables stands at -$723,000 for Q3 2025, versus -$1.3 million for Q2 2025 and $873,000 for Q1 2025.